$NTRA

Natera, Inc.

11
2
0
$12.0M
Sheena Jonathan
100%

Sheena Jonathan sold $2.9M of NTRA

Sheena Jonathan sold 9,150 shares of Natera, Inc. (NTRA) at an average of $315.66 ($308.40–$320.90, $2.89M total) across 10 trades on 2026-08-07 under a Rule 10b5-1 trading plan.

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

NTRA sentiment & insider activity

Over the past 7 days, alphai's AI scored 13 news stories mentioning NTRA (Natera, Inc.). Coverage has skewed bullish: 11 bullish, 2 neutral, and 0 bearish.

Recent NTRA coverage spans earnings, insider activity and market movers.

In the last 30 days, NTRA insiders filed 62 SEC Form 4 transactions — no purchases and 62 sales ($12.0M). The most active reporter was Sheena Jonathan with 27 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.

What's driving NTRA

  • This is a routine insider sale under a pre-arranged 10b5-1 plan, with limited signal value for near-term fundamentals.

    SEC EDGAR · Aug 8, 2026

  • This is a routine insider sale disclosure, not an operational or financial update, but it can slightly affect near-term sentiment and positioning.

    SEC EDGAR · Aug 8, 2026

  • Beat plus guidance hike likely drives near-term repricing and momentum trading, with additional upside from PMDA submission for Signatera.

    stockstotrade.com · Aug 7, 2026

  • The article attributes the move to an earnings beat plus a guidance hike, implying near-term repricing and momentum continuation risk.

    timothysykes.com · Aug 7, 2026

  • The text frames a post-earnings upside catalyst via a Q2 beat and raised 2026 revenue outlook, driving momentum trading.

    timothysykes.com · Aug 7, 2026

alphai scores every news story that mentions NTRA with an AI model for sentiment and relevance, and aggregates insider trades from Natera, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NTRA

Score
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

$SPCXLow

SpaceX's influence ripples across markets: AlphaCheck

A Yahoo Finance AlphaSpace market check said stocks rose early as a weak jobs report supported expectations the Federal Reserve will hold rates. The Nasdaq Composite (^IXIC) gained about 0.5%. The article highlights SpaceX (SPCX) remarks on Starlink targeting AT&T, Verizon and T-Mobile, and Musk comments on building 20 gigawatts of power, affecting telecom and power-related stocks, plus Nvidia (NVDA) after SpaceX chose Nvidia.

Related tickers